These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1398412)

  • 1. [Gemfibrozil in the differential therapy of disorders of fat metabolism].
    Ebner F
    Fortschr Med; 1992 Oct; 110(28):523-6. PubMed ID: 1398412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of gemfibrozil therapy for raising high density lipoprotein levels.
    Weis S; Kudchodkar BJ; Clearfield MB; Lacko AG
    Artery; 1992; 19(6):353-66. PubMed ID: 1471924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gemfibrozil in the treatment of lipid metabolism disorders].
    Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Klin Med (Mosk); 1994; 72(1):37-41. PubMed ID: 8196321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in lipid status during pravastatin treatment].
    Craveri A; Colombo L; Citella C; Pedrazzini L; Altomare S; Giavardi L; Picollo S; Vignati A; Lanfredini M
    Minerva Med; 1992 Nov; 83(11):695-703. PubMed ID: 1461540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
    Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
    Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
    Berioli S; Bentivoglio M; Conti R; Osanna RA; Savino K; Zollino L; Corea L
    Cardiologia; 1990 Apr; 35(4):335-40. PubMed ID: 2245435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical trial of lovastatin versus gemfibrozil in the treatment of primary hypercholesterolemia].
    Catalán M; López de Ocáriz A; Alvarez MP; Ariño M; Azanza JR; Honorato J
    Rev Med Univ Navarra; 1992; 37(3):127-33. PubMed ID: 1480917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
    Lewis SJ
    Am J Med; 2009 Jan; 122(1 Suppl):S38-50. PubMed ID: 19110087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
    Stange EF; Osenbrügge M; Rustan M; Reimann F; Schneider A; Ditschuneit HH; Ditschuneit H
    Atherosclerosis; 1991 Dec; 91(3):257-65. PubMed ID: 1789808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which patients need aggressive lipid-altering therapy?
    Hunninghake DB
    Cleve Clin J Med; 1993; 60(6):483-4. PubMed ID: 8287511
    [No Abstract]   [Full Text] [Related]  

  • 19. Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials.
    Doi T; Langsted A; Nordestgaard BG
    J Intern Med; 2024 May; 295(5):707-710. PubMed ID: 38343109
    [No Abstract]   [Full Text] [Related]  

  • 20. High-density lipoprotein cholesterol elevation with gemfibrozil: effects of baseline level and modifying factors.
    Mänttäri M; Tenkanen L; Mäenpää H; Manninen V; Huttunen JK
    Clin Pharmacol Ther; 1993 Oct; 54(4):437-47. PubMed ID: 8222487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.